Elder Pharma targets 20% growth in revenues this fiscal

Elder Pharmaceuticals is looking 20% growth in revenues to around Rs 1,200 crore in the current fiscal on the back of new product launches. The company is targeting to achieve the growth in the domestic market by its existing strong range of branded products including Shelcal, Eldervit and Chymoral as well as further brand building of its new product range.

The Mumbai-based firm, which derives 95% of its revenues from the domestic market, is also expecting a better performance from its in-licensed brands and overseas subsidiaries. Last year, the company had a turnover of about Rs 1,000 crore on a consolidated basis with maximum traction in women's healthcare, wound care and the nutraceutical segments.

At present, the company has 24 in-licence agreements with various firms for the domestic market.

The company has around six manufacturing units in India, all as per international standards. Post increasing its stake in Elder Biomeda AD and Neutrahealth PLC, EPL also has access to the manufacturing units of these companies in Bulgaria and Birmingham, UK respectively coupled with distribution network and brands of the same.